← Leaderboards
Xiaoying Wang
Tulane University Of Louisiana
$10,717,451
Attributed
$10,717,451
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,717,451 · 6
By mechanism
R01$8,467,899 · 5
U01$2,249,552 · 1
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Christopher Williams$5,047,884
- Wenke Feng$7,762,867
- Frank B. Cogswell$1,205,497
- Partha Chandra$984,666
- Vida A Dennis$399,784
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainInsightNeurological OutcomeRecombinantsCerebrumBlood VesselsBlood - Brain Barrier AnatomyStrokeMediatingRecoveryWestern BlottingExtravasationAcuteProteinsResearch StudyNeuronsReverse Transcriptase Polymerase Chain ReactionTight JunctionsIn VitroRecovery Of FunctionImmunohistochemistrySignal TransductionInjuryPrograms
Grant awards (28)
Role of Irg-1/itaconate in modulating secondary brain damage after traumatic brain injury in mice$392,426
R01 · FY2025 · NS · contact PI
Role of Irg-1/itaconate in modulating secondary brain damage after traumatic brain injury in mice$422,947
R01 · FY2024 · NS · contact PI
Role of Irg-1/itaconate in modulating secondary brain damage after traumatic brain injury in mice$434,602
R01 · FY2023 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$332,500
R01 · FY2020 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$251,207
R01 · FY2019 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$223,627
R01 · FY2019 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$129,212
R01 · FY2019 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$119,127
R01 · FY2019 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$375,445
R01 · FY2018 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$370,335
R01 · FY2018 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$375,445
R01 · FY2017 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$370,335
R01 · FY2017 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$375,445
R01 · FY2016 · NS · contact PI
Recombinant FGF21 as a novel approach for treating ischemic stroke in type 2 diabetes$370,335
R01 · FY2016 · NS · contact PI
Annexin A2 as a cerebrovascular therapy in traumatic brain injury$375,445
R01 · FY2015 · NS · contact PI
Recombinant annexin A2 plus tPA for combination stroke therapy$369,112
R01 · FY2014 · NS · contact PI
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy$1
U01 · FY2014 · NS · contact PI
Recombinant annexin A2 plus tPA for combination stroke therapy$359,792
R01 · FY2013 · NS · contact PI
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy$1,399,190
U01 · FY2012 · NS · contact PI
Recombinant annexin A2 plus tPA for combination stroke therapy$372,841
R01 · FY2012 · NS · contact PI
Development of annexin A2 plus tPA as a novel stroke thrombolytic therapy$850,361
U01 · FY2011 · NS · contact PI
Recombinant annexin A2 plus tPA for combination stroke therapy$372,841
R01 · FY2011 · NS · contact PI
Recombinant annexin A2 plus tPA for combination stroke therapy$380,450
R01 · FY2010 · NS · contact PI
Neuroprotective Mechanisms of Neuroglobin in Stroke$334,170
R01 · FY2010 · NS · contact PI
Neuroprotective Mechanisms of Neuroglobin in Stroke$337,545
R01 · FY2009 · NS · contact PI
Neuroprotective Mechanisms of Neuroglobin in Stroke$337,545
R01 · FY2008 · NS · contact PI
Neuroprotective Mechanisms of Neuroglobin in Stroke$337,545
R01 · FY2007 · NS · contact PI
Neuroprotective Mechanisms of Neuroglobin in Stroke$347,625
R01 · FY2006 · NS · contact PI